About Sunesis Pharmaceuticals (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton's tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Trailing P/E Ratio-2.10526315789474
Forward P/E Ratio-2.79
Sales & Book Value
Price / Sales148.68
Price / CashN/A
Book Value$0.02 per share
Price / Book145.00
Return on EquityN/A
Return on Assets-128.72%
Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals (NASDAQ:SNSS) released its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. View Sunesis Pharmaceuticals' Earnings History.
Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2018?
4 analysts have issued twelve-month target prices for Sunesis Pharmaceuticals' shares. Their predictions range from $2.48 to $7.00. On average, they anticipate Sunesis Pharmaceuticals' share price to reach $4.49 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.
What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (3/14/2018)
- 2. Cantor Fitzgerald analysts commented, "SNS-062 Data Now 3Q18. SNSS disclosed that it now expects to complete the Phase Ib trial of SNS-062 in fall 2018, which we interpret as early 4Q18, though it could be late 3Q18. The second dose cohort (50 mg) has not yet completed, but since a Phase Ia in healthy volunteers was run, our expectation has been that it would not take many doses to identify the Phase II dose (RP2D). While the reasons for the delay (rapidly progressing patient, non-drug related AE) are understandable, we think the disclosure could cause the shares to pull back." (3/8/2018)
- 3. Cowen Inc analysts commented, "Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of." (11/2/2017)
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include CTI BioPharma (CTIC), Recro Pharma (REPH), Verona Pharma plc - American Depositary Share (VRNA), Miragen Therapeutics (MGEN), Synlogic (SYBX), Compugen (CGEN), Nymox Pharmaceutical (NYMX), Corvus Pharmaceuticals (CRVS), Tyme Technologies (TYME), Selecta Biosciences (SELB), Nabriva Therapeutics (NBRV), Spero Therapeutics (SPRO), Kamada (KMDA), Zafgen (ZFGN), Ra Pharmaceuticals (RARX), Spring Bank Pharmaceuticals (SBPH), Ovid Therapeutics (OVID) and Aratana Therapeutics (PETX).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Mr. Dayton Misfeldt, Interim CEO & Director (Age 44)
- Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 55)
- Mr. William P. Quinn, CFO and Sr. VP of Fin. & Corp. Devel.
- Mr. Gene C. Jamieson, VP of Technical Operations
- Dr. Judith A. Fox Ph.D., Chief Scientific Officer
Has Sunesis Pharmaceuticals been receiving favorable news coverage?
Press coverage about SNSS stock has been trending somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a news sentiment score of 0.17 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 48.06 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Sunesis Pharmaceuticals' major shareholders?
Sunesis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vatera Holdings LLC (0.53%), BlackRock Inc. (0.38%), Geode Capital Management LLC (0.37%) and Wells Fargo & Company MN (0.14%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt, Geoffrey M Parker and Mpm Oncology Impact Management. View Institutional Ownership Trends for Sunesis Pharmaceuticals.
Which major investors are selling Sunesis Pharmaceuticals stock?
Which major investors are buying Sunesis Pharmaceuticals stock?
SNSS stock was bought by a variety of institutional investors in the last quarter, including Vatera Holdings LLC, Geode Capital Management LLC and BlackRock Inc.. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt, Geoffrey M Parker and Mpm Oncology Impact Management. View Insider Buying and Selling for Sunesis Pharmaceuticals.
How do I buy shares of Sunesis Pharmaceuticals?
Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of SNSS stock can currently be purchased for approximately $2.90.
How big of a company is Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals has a market capitalization of $115.07 million and generates $670,000.00 in revenue each year. The biopharmaceutical company earns $-35,450,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. Sunesis Pharmaceuticals employs 34 workers across the globe.
How can I contact Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]
MarketBeat Community Rating for Sunesis Pharmaceuticals (SNSS)MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sunesis Pharmaceuticals (NASDAQ:SNSS) Earnings History and Estimates Chart
Sunesis Pharmaceuticals (NASDAQ SNSS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017||Q3 2017||($0.37)||($0.43)||$0.37 million||View||N/A|
|7/27/2017||Q2 2017||($0.76)||($0.41)||$2.40 million||View||N/A|
|5/8/2017||Q1 2017||($0.83)||($0.47)||$1.57 million||$0.67 million||View||Listen|
|3/9/2017||Q4 2016||($0.43)||($0.44)||$0.60 million||$0.68 million||View||Listen|
|11/3/2016||Q316||($0.71)||($0.62)||$0.60 million||$0.60 million||View||N/A|
|7/29/2016||Q216||($0.10)||($0.12)||$0.70 million||$0.60 million||View||Listen|
|5/5/2016||Q116||($0.12)||($0.12)||$0.77 million||$0.64 million||View||Listen|
|3/10/2016||Q415||($0.14)||($0.15)||$0.84 million||$0.67 million||View||Listen|
|11/5/2015||Q315||($0.12)||($0.09)||$1.09 million||$0.68 million||View||Listen|
|7/30/2015||Q215||($0.13)||($0.15)||$1.21 million||$0.85 million||View||N/A|
|5/5/2015||Q115||($0.16)||($0.13)||$1.14 million||$0.90 million||View||Listen|
|3/12/2015||Q414||($0.20)||($0.02)||$1.17 million||$0.90 million||View||Listen|
|11/10/2014||Q314||($0.17)||($0.25)||$1.97 million||$0.85 million||View||Listen|
|8/5/2014||Q214||($0.17)||($0.20)||$1.32 million||$2.00 million||View||Listen|
|5/7/2014||Q114||($0.17)||($0.26)||$1.32 million||$2.00 million||View||Listen|
|3/6/2014||Q413||($0.20)||($0.15)||$1.37 million||$2.00 million||View||Listen|
|11/12/2013||Q313||($0.20)||($0.16)||$1.44 million||$1.99 million||View||Listen|
|7/29/2013||Q2 2013||($0.21)||$0.18||$1.22 million||$1.99 million||View||Listen|
|5/9/2013||Q1 2013||($0.20)||($0.23)||$0.75 million||$1.99 million||View||Listen|
|3/13/2013||Q4 2012||($0.19)||($0.20)||$0.32 million||$1.99 million||View||Listen|
|11/8/2012||Q312||($0.11)||($0.37)||$4.17 million||$0.26 million||View||N/A|
Sunesis Pharmaceuticals (NASDAQ:SNSS) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.04 EPS
Next Year EPS Consensus Estimate: $-1.15 EPS
Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com
Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 53.04%
Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/6/2017||Mpm Oncology Impact Management||Major Shareholder||Buy||81,500||$2.77||$225,755.00|| |
|11/2/2017||Mpm Oncology Impact Management||Major Shareholder||Buy||25,300||$2.59||$65,527.00|| |
|10/27/2017||Dayton Misfeldt||Director||Buy||400,000||$2.00||$800,000.00|| |
|12/9/2016||Geoffrey M Parker||Director||Buy||3,740||$3.87||$14,473.80||65,151|| |
|5/26/2016||Geoffrey M Parker||Director||Buy||9,500||$0.47||$4,465.00||62,005|| |
|5/25/2016||Geoffrey M Parker||Director||Buy||52,505||$0.47||$24,677.35||30,000|| |
|12/21/2015||Dayton Misfeldt||Director||Buy||1,750,000||$0.84||$1,470,000.00|| |
|8/25/2015||Daniel N Swisher Jr||CEO||Buy||12,216||$1.01||$12,338.16||179,510|| |
|8/24/2015||Daniel N Swisher Jr||CEO||Buy||12,784||$1.01||$12,911.84||179,510|| |
|8/29/2014||Forest Baskett||Major Shareholder||Sell||266,700||$7.97||$2,125,599.00|| |
|8/28/2014||Bay City Capital Llc||Major Shareholder||Sell||300,700||$7.98||$2,399,586.00|| |
|8/28/2014||Dayton Misfeldt||Director||Sell||200,000||$7.89||$1,578,000.00|| |
|8/27/2014||Adam R Craig||CMO||Sell||2,554||$8.00||$20,432.00|| |
|8/27/2014||Daniel N Swisher Jr||CEO||Sell||5,000||$8.00||$40,000.00|| |
|8/27/2014||Dayton Misfeldt||Director||Sell||100,700||$8.16||$821,712.00|| |
|8/27/2014||Eric Bjerkholt||CFO||Sell||10,000||$8.00||$80,000.00|| |
|8/27/2014||Krishna Kittu Kolluri||Major Shareholder||Sell||108,300||$8.17||$884,811.00|| |
|8/12/2014||Dayton Misfeldt||Director||Sell||743,700||$6.64||$4,938,168.00|| |
|8/12/2014||Equity Opportunities Fu Growth||Major Shareholder||Sell||710,540||$6.63||$4,710,880.20|| |
Sunesis Pharmaceuticals (NASDAQ SNSS) News Headlines
|Sunesis Pharmaceuticals (SNSS) Expected to Announce Earnings of -$0.29 Per Share|
www.americanbankingnews.com - March 20 at 9:08 PM
|Sunesis Pharmaceuticals (SNSS) Lowered to Strong Sell at Zacks Investment Research|
www.americanbankingnews.com - March 14 at 5:24 PM
|Sunesis Pharmaceuticals to Present at Upcoming Investor Conferences|
feeds.benzinga.com - March 14 at 4:55 PM
|Research Analysts Issue Forecasts for Sunesis Pharmaceuticals, Inc.'s FY2018 Earnings (SNSS)|
www.americanbankingnews.com - March 14 at 9:50 AM
|Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual ... - GlobeNewswire (press release)|
globenewswire.com - March 14 at 9:20 AM
|Sunesis Offers A Great Buying Opportunity After Dip Due To Delay Of Cancer Data - Seeking Alpha|
seekingalpha.com - March 14 at 9:20 AM
|Sunesis Pharmaceuticals (SNSS) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow|
seekingalpha.com - March 13 at 6:55 PM
|Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference|
finance.yahoo.com - March 13 at 8:57 AM
|Sunesis Pharmaceuticals (SNSS) vs. Prosensa (RNA) Head-To-Head Review|
www.americanbankingnews.com - March 13 at 1:18 AM
|Sunesis Pharmaceuticals, Inc. to Post FY2021 Earnings of ($0.42) Per Share, Oppenheimer Forecasts (SNSS)|
www.americanbankingnews.com - March 12 at 9:40 AM
|Sunesis Pharmaceuticals (SNSS) Announces Quarterly Earnings Results|
www.americanbankingnews.com - March 9 at 6:35 PM
|Cantor Fitzgerald Reaffirms "Hold" Rating for Sunesis Pharmaceuticals (SNSS)|
www.americanbankingnews.com - March 9 at 12:10 AM
|Sunesis Pharmaceuticals, Inc. to Host Earnings Call|
finance.yahoo.com - March 8 at 6:08 PM
|Sunesis Pharmaceuticals Q4 Earnings Preview|
finance.yahoo.com - March 8 at 6:08 PM
|Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights|
finance.yahoo.com - March 8 at 6:08 PM
|Are Earnings Prospects Improving For Loss-Making Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS)?|
finance.yahoo.com - March 7 at 8:52 AM
|Sunesis Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference|
finance.yahoo.com - March 6 at 8:43 AM
|BIO-TECHNE (TECH) vs. Sunesis Pharmaceuticals (SNSS) Critical Comparison|
www.americanbankingnews.com - March 5 at 11:36 AM
|Sunesis Pharmaceuticals (SNSS) Lowered to Strong Sell at ValuEngine|
www.americanbankingnews.com - March 4 at 9:52 AM
|-$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter|
www.americanbankingnews.com - March 3 at 5:24 PM
|Sunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 ... - GlobeNewswire (press release)|
globenewswire.com - March 3 at 8:42 AM
|Sunesis Pharmaceuticals, Inc. (SNSS) Given Consensus Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - March 1 at 12:10 PM
|Sunesis Pharmaceuticals (SNSS) to Release Quarterly Earnings on Wednesday|
www.americanbankingnews.com - February 28 at 1:58 AM
|Investors Buy High Volume of Sunesis Pharmaceuticals Call Options (SNSS)|
www.americanbankingnews.com - February 23 at 8:26 AM
|Sunesis Pharmaceuticals (SNSS) Downgraded by Zacks Investment Research to "Sell"|
www.americanbankingnews.com - February 15 at 2:08 PM
|Sunesis Pharmaceuticals (SNSS) Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - February 9 at 2:16 PM
|Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors|
finance.yahoo.com - February 8 at 8:29 AM
|Sunesis Pharmaceuticals, Inc. (SNSS) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - February 4 at 11:14 AM
|Reviewing Fibrocell Science (FCSC) and Sunesis Pharmaceuticals (SNSS)|
www.americanbankingnews.com - January 15 at 5:10 PM
|Sunesis Pharmaceuticals (SNSS) and PRA Health Sciences (PRAH) Head to Head Contrast|
www.americanbankingnews.com - January 14 at 3:58 AM
|Financial Survey: WuXi PharmaTech (Cayman) (WX) versus Sunesis Pharmaceuticals (SNSS)|
www.americanbankingnews.com - January 13 at 11:34 PM
|Sunesis Pharmaceuticals, Inc. (SNSS) Expected to Announce Earnings of -$0.25 Per Share|
www.americanbankingnews.com - January 12 at 3:14 AM
|Sunesis Pharmaceuticals, Inc. (SNSS) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - January 10 at 8:18 AM
|Mid-Day Market Update: Buckle Drops After December Sales Results; ChemoCentryx Shares Spike Higher|
www.nasdaq.com - January 4 at 3:27 PM
|Zacks: Brokerages Expect Sunesis Pharmaceuticals, Inc. (SNSS) Will Post Earnings of -$0.25 Per Share|
www.americanbankingnews.com - December 26 at 4:07 PM
|-$0.25 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter|
www.americanbankingnews.com - December 26 at 4:07 PM
|Reviewing Sunesis Pharmaceuticals (SNSS) and Synageva Biopharma (GEVA)|
www.americanbankingnews.com - December 24 at 3:22 AM
|Stocks to watch next week - Apple Inc. (NASDAQ:AAPL) | Seeking ... - Seeking Alpha|
seekingalpha.com - December 23 at 9:13 PM
|Sunesis Pharmaceuticals, Inc. (SNSS) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - December 16 at 8:46 AM
|Sunesis Pharmaceuticals (SNSS) Now Covered by Oppenheimer|
www.americanbankingnews.com - December 14 at 3:26 PM
|Pre-Open Movers 12/11: (BLUE) (BPMC) (SNSS) Higher; (SYRS) (ONCE) (GBT) Lower (more...)|
www.streetinsider.com - December 13 at 3:28 PM
|ARGX Soars, SNSS Catches Eyes, BPMC, BLUE Turn Heads, FDA Nod For SNNA|
www.nasdaq.com - December 12 at 3:27 PM
|Wells Fargo Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to ... - StreetInsider.com|
www.streetinsider.com - December 12 at 8:56 AM
|Sunesis Pharmaceuticals (SNSS) Upgraded at Wells Fargo & Company|
www.americanbankingnews.com - December 11 at 7:52 PM
|Sunesis Pharmaceuticals (SNSS) PT Set at $3.00 by Cantor Fitzgerald|
www.americanbankingnews.com - December 11 at 9:46 AM
|Top Analyst Upgrades and Downgrades: ADP, Bluebird Bio, DaVita, First Solar, Square, SunPower, US Steel and More|
247wallst.com - December 11 at 9:31 AM
|Sunesis Pharmaceuticals (SNSS) and Its Peers Head-To-Head Comparison|
www.americanbankingnews.com - December 5 at 11:36 PM
|Sunesis Pharmaceuticals to Provide Program Update for Non ... - GlobeNewswire (press release)|
globenewswire.com - December 5 at 3:27 PM
|Sunesis Pharmaceuticals Announces Change in Leadership - GlobeNewswire (press release)|
globenewswire.com - December 5 at 3:27 PM
|Wells Fargo Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Market Perform - StreetInsider.com|
www.streetinsider.com - December 5 at 3:27 PM
Sunesis Pharmaceuticals (NASDAQ:SNSS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sunesis Pharmaceuticals (NASDAQ:SNSS) Income Statement, Balance Sheet and Cash Flow Statement
Sunesis Pharmaceuticals (NASDAQ SNSS) Stock Chart for Friday, March, 23, 2018